Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procept BioRobotics Corp.

www.procept-biorobotics.com

Latest From Procept BioRobotics Corp.

Pacts In Medtech: Glaukos To Distribute Saten's MicroShunt; Acell Signs Distribution Deals

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.

Pacts in Medtech Deals

Results Recap: EndoBarrier Improves Obesity And Diabetes Outcomes In UK Study; Procept’s Aquablation Proves Effective Again

Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition covers new clinical data released March 8 to March 22, not including the data presented at the annual conferences of the American Academy of Orthopedic Surgeons or American College of Cardiology, which are presented in separate special editions of Results Recap.

Tracking Trials Clinical Trials

Procept's Aquablation BPH Therapy Gets Boost From UK NICE Guidance

The UK's NICE issued a recommendation approving Procept's AquaBeam Aquablation therapy as an alternative to surgical treatments for benign prostate hyperplasia just as a Medciare new technology add-on payment takes effect for Aquablation in the US.

Market Access United Kingdom

Three Devices Gain Medicare Add-Ons, Including Boston Sci's New TAVR Protector

The US Medicare agency granted inpatient new-technology add-on payments for Boston Scientific's newly acquired cerebral protection system for TAVR, Respicardia's neurostimulator for sleep apnea and Procept BioRobotics' novel resection system for benign prostatic hyperplasia. The highly selective bonus payments typically help drive adoption for the chosen new technologies.

Reimbursement Market Access
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Procept BioRobotics Corp.
  • Senior Management
  • Nikolai Aljuri, PhD, CEO
    Surag Mantri, SVP, R&D
    Matthew Salkeld, VP, Sales & Mktg.
    Eric Steuben, VP, Operations
    Barry Templin, VP, Corp. Strategy
  • Contact Info
  • Procept BioRobotics Corp.
    Phone: (650) 232-7222
    900 Island Dr.
    Ste. 210
    Redwood Shores, CA 94065
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register